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Introduction: Metabolic abnormalities may exacerbate the risk of adverse outcomes
in patients with type 2 diabetes mellitus. The present study aims to assess the predic-
tive value of HbA1c and lipid variability on the risks of sudden cardiac death (SCD)
and incident atrial fibrillation (AF).
Methods: The retrospective observational study consists of type 2 diabetic patients
prescribed with insulin, who went to publicly funded clinics and hospitals in Hong
Kong between January 1, 2009 and December 31, 2009. Variability in total choles-
terol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-
cholesterol (HDL-C), triglyceride, and HbA1c were assessed through their SD and
coefficient of variation. The primary outcomes were incident (1) ventricular tachycar-
dia/ventricular fibrillation, actual or aborted SCD and (2) AF.
Results: A total of 23 329 patients (mean ± SD age: 64 ± 14 years old; 51% male;
mean HbA1c 8.6 ± 1.3%) were included. On multivariable analysis, HbA1c, total
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cholesterol, LDL-C and triglyceride variability were found to be predictors of
SCD (p < .05).
Conclusion: HbA1c and lipid variability were predictive of SCD. Therefore, poor glu-
cose control and variability in lipid parameters in diabetic patients are associated with
aborted or actual SCD. These observations suggest the need to re-evaluate the
extent of glycemic control required for outcome optimization.
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1 | INTRODUCTION
Sudden cardiac death (SCD) is a leading cause of death worldwide,
accounting for approximately 25% of deaths of cardiovascular origin.1
By contrast, atrial fibrillation (AF), the most common sustained
arrhythmia amongst adults, is increasingly prevalent around the world,
particularly amongst developed countries.2,3 Significant increases in
morbidity and mortality amongst large-scale epidemiological studies
have been demonstrated amongst AF patients, including an increase
in SCD risk.4–7 Furthermore, type 2 diabetes mellitus increases the
risk of SCD, as demonstrated by a recent meta-analysis of population-
based prospective studies.8
With the global shift towards a more personalized approach in
the management of diabetes, there is an increasing interest in explor-
ing the application of new parameters, such as HbA1c and lipid vari-
ability, to better monitor disease progression and evaluate the
prognosis. Although the exact mechanisms remain unclear, increased
long-term glycemic and lipid variability is hypothesized to lead to
endothelial dysfunction via an increase in oxidative stress.9–11 Since
hemoglobin has an average lifespan of 100 days, HbA1c can reflect
glycemic control in recent months. Therefore, HbA1c variability is not
affected by short-term glycemic changes due to diet and medication
changes, thus it is a better representation of long-term glycemic varia-
tion. However, existing studies have focused on risk prediction of all-
cause mortality and general cardiovascular adverse events,12–16 with
a limited number of studies exploring specifically arrhythmic risks
amongst diabetics. Moreover, those type 2 diabetics who are partially
or fully dependent on insulin are more likely to have severe disease
and may be at higher risks of arrhythmias.
The aim of the present study was to assess the predictive value of
HbA1c and lipid variability towards aborted or successful SCD, as well
as incident AF in type 2 diabetic patients receiving insulin therapy.
2 | METHODS
This study is a retrospective observational study approved by The
Joint Chinese University of Hong Kong – New Territories East Cluster
Clinical Research Ethics Committee (Application reference: 2018.462,
2018.643, 2019.361 [approval date: 15th August 2019]). The study
cohort contains type 2 diabetic patients with insulin prescribed from
any hospitals and outpatient clinics under the Hong Kong Hospital
Authority from January 1, 2009 to December 31, 2009. The study
cohort from 10 years ago was selected to ensure there is adequate
follow-up especially for rarer events such as ventricular arrhythmias
and SCD. Clinical and biochemical data of eligible patients were
obtained through the clinical data analysis and reporting system
(CDARS), an electronic healthcare record database that integrates
data across all publicly funded hospitals and clinics in Hong Kong. This
system has been used by our team and other teams to conduct
population-based studies on different cardiovascular diseases,17–20
including diabetes mellitus,21 in the past.
2.1 | Patient data
Clinical and biochemical data of the present cohort were extracted
from CDARS. The outcomes of the present study are the occurrence
of SCD and AF from January 1, 2009 to December 31, 2019. SCD is
defined as episodes of VT, VF, or nonspecific cardiac arrest, which
were diagnosed under clinical judgment with electrocardiographic or
biochemical findings and subsequently coded into hospital records.
Both aborted and actual SCD events were included. VT/VF on elec-
trophysiological study is not included. Hypoglycemia-induced cases of
SCD or AF were defined as cases with dextrose infusion during the
admission episode or had blood glucose measured ≤3.9 mg/mmol.
Demographic details, including age and sex, were extracted. Patients
were categorized into four groups based on their age: below age
55, between ages 55 and 64, between ages 65 and 74, above and
include age 75. The number of baseline acute hospitalization episodes
between January 1, 2004 and December 31, 2008 was also obtained.
Furthermore, the average daily dose of different classes of cardiovas-
cular medications and antidiabetic agents was calculated by averaging
the multiple between the daily dose frequency and drug dose by all
patients with prescriptions of the specific drug class. Eight classes of
antidiabetic agents were examined: Insulin, sulphonylurea, biguanide,
alpha-glucosidase inhibitor, thiazolidinedione, dipeptidyl peptidase-4
inhibitor (DPP-4I), glucagon-like peptide receptor-1 agonist (GLPA),
and meglitinide. Data on five classes of cardiovascular drugs were
obtained: angiotensinogen-converting-enzyme inhibitor/angiotensin
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receptor blocker (ACEI/ARB), beta-adrenergic inhibitor, calcium chan-
nel blocker (CCB), diuretics, and lipid-lowering agents
In terms of patient comorbidities, the number of nondiabetic
comorbidities and diabetes-related complications between January
1, 1999 and December 31, 2008 were obtained. The specific diabetic-
related complications recorded include: (1) Amyotrophy, (2) Arthropa-
thy, (3) Hyperosmolar hyperglycemic state/diabetic ketoacidosis,
(4) Hypoglycemia, (5) Neuropathy, (6) Retinopathy/maculopathy,
(7) Peripheral vascular disease/angiopathy, and (8) Nephropathy.
Patient's past medical history of the following conditions that initiated
F IGURE 1 (A) Kaplan–Meier
survival curves of different age
groups for sudden cardiac death.
(B) Kaplan–Meier survival curves of
different age groups for atrial
fibrillation
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between January 1, 1999 and December 31, 2008 were also
extracted: (1) Chronic kidney disease (CKD), (2) Chronic obstructive
pulmonary disease (COPD), (3) Chronic liver disease (CLD), (4) Heart
failure (HF), (5) Ischemic heart disease (IHD), (6) Hypertension,
(7) Acute myocardial infarction, and (8) Stroke. International classifica-
tion of disease, ninth edition (ICD-9) codes was used to extract the
study outcomes and pre-existing comorbidities (Supplementary
Table 1), whilst the diabetic complications were extracted using the
ICD-9 based hospital authority master disease code table for greater
specificity.
Baseline data of urinalysis, renal and liver function tests, complete
blood count, and other blood tests within the year 2008 were
extracted. Urinalysis results include: (1) Urine albumin/creatinine ratio,
(2) Creatinine clearance, (3) 24-hours total urine protein and albumin,
(4) Spot urine protein, albumin, and glucose. Indices from complete
blood count include: (1) The absolute number of hemoglobin, basophil,
eosinophil, platelet, red and white blood cell, (2) Mean corpuscular
volume, (3) Mean corpuscular hemoglobin concentration, (4) Mean
corpuscular hemoglobin (MCH), (5) Hematocrit. The presence of anae-
mia, defined by sex-based thresholds of below 13 g/dl for male and
12 g/dl for female, were obtained. Blood test results extracted
include: (1) Serum creatinine, (2) Serum sodium and potassium,
(3) Serum urea and urate, (4) Total serum protein and albumin, (5) Total
serum bilirubin, alanine aminotransferase and alkaline phosphatase,
(6) Fasting and random blood glucose. The presence of hypoglycemia
at baseline and frequency of hypoglycemic episodes were extracted.
Hypoglycemia was defined by fasting or random blood glucose below
3.9 mg/mmol.
The following blood results between January 1, 2004 and
December 31, 2008 were extracted for the evaluation of their mean,
variability and baseline value: (1) Total cholesterol, (2) High-density
lipoprotein cholesterol (HDL-C), (3) Low-density lipoprotein choles-
terol (LDL-C), (4) Total triglyceride, and (5) HbA1c. LDL-C results
included findings from both direct and calculated measurements. Vari-
ability analysis of a biochemical index was only executed on patients
with at least three measurements.
2.2 | Statistical analysis
Statistical analysis was performed using R Studio, and statistical signif-
icance was defined as p value <.05. Kaplan–Meier survival curve was
used to portray the difference in actual or aborted SCD and AF sur-
vival between patients of different age groups, with the statistical sig-
nificance of the intergroup difference evaluated using the log-rank
test. Temporal variability of HbA1c and lipid indices were evaluated
using calculated parameters of SD and coefficient of variation (CV).
CV was measured by multiplying 100-fold of the value calculated by
the ratio SD and mean. SD and CV were used to measure variability
since they were less affected by outliers. Whilst SD is independent of
the mean, CV is independent of the scale thus more sensitive to small
changes to the mean. To identify predictors for shorter time to aborted
or actual SCD and AF occurrence, univariable Cox regression was first
applied to clinical and biochemical parameters. Patients with missing data
were excluded from the analysis. Furthermore, due to their limited pre-
scription towards the study cohort, GLPA and meglitinide were not
included. Subsequently, parameters with p value <0.10 were included in
the multivariable Cox regression model. Only patients with no missing
data for the selected parameters, and at least three measurements for
the selected variability predictors, were included in the multivariate
models. No data imputation was performed.
The inter-relations between HbA1c and lipid variability with inter-
mittent hypoglycemia were evaluated using logistic and Poisson
regression. Logistic regression was also used to examine the relation-
ship between baseline hypoglycemia frequency and (1) occurrence of
SCD/AF or (2) aborted or actual SCD/AF episodes that were associ-
ated with hypoglycemia. Odds ratios (ORs) were reported from logis-
tic and Poisson regression, whereas hazard ratios were reported from
Cox regression, along with the 95% confidence intervals.
3 | RESULTS
The present study included 23 329 patients (mean age = 64.3 ± 13.8,
male = 50.8%, average mean HbA1c = 8.6 ± 1.3%, all-cause mortal-
ity = 50.5%). The cohort was divided into four age groups: <55
(n = 5511), 55–64 (n = 5745), 65–74 (n = 6032), >75 (n = 6041), with
a significant intergroup difference in survival for both aborted or
actual SCD (p < .0001) and incident AF (p < .0001; Figure 1A, B). The
baseline clinical and biochemical characteristics of the cohort are
TABLE 1 Baseline clinical characteristics
n %
Male 11 842 50.8
Comorbidities
Chronic kidney disease 2099 9.00
Chronic obstructive pulmonary disease 783 3.36
Heart failure 2355 10.1
Ischemic heart disease 3904 16.7
Hypertension 8538 36.6
Chronic liver disease 1335 5.72











Peripheral vascular disease/angiopathy 544 2.33
Nephropathy 3420 14.7
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TABLE 2 Baseline biochemical characteristics
Mean SD
Urinalysis
Albumin/creatinine ratio (mg/mmol) 40.3 125
Creatinine clearance (ml/min) 52.9 35.2
Spot protein (g/d) 1.19 1.96
Spot albumin (mg/L) 179 555
Spot glucose (mmol/L) 12.5 6.54
24-hours total protein (g/d) 1.20 1.99
24-hours total albumin (mg/d) 279 677
Baseline blood test
Fasting glucose (mmol/L) 8.90 3.66
Random glucose (mmol/L) 12.2 7.36
HbA1c (%) 8.56 1.93







Direct LDL cholesterol (mmol/L) 2.81 0.924




Free thyroxine (fT4) (pmol/L) 14.7 37.3
Renal function test
Creatinine (umol/L) 146 160
Sodium (mmol/L) 139 3.33
Potassium (mmol/L) 4.31 0.507
Urate (umol/L) 0.412 0.128
Urea (mmol/L) 8.98 6.11
Liver function test
Albumin (g/L) 39.1 5.53
Alanine aminotransferase (ALT) (U/L) 24.3 21.0
Alkaline phosphatase (ALP) (U/L) 84.5 45.8
Total bilirubin (umol/L) 11.2 9.07
Total protein (g/L) 74.4 7.14
Complete blood count







Mean corpuscular volume (MCV) (fL) 87.2 7.42
Hematocrit (L/L) 0.376 0.559
Basophil (109/L) 0.029 0.042
Eosinophil (109/L) 0.225 0.236
Lymphocyte (109/L) 1.87 0.866
Monocyte (109/L) 0.539 0.266
Neutrophil (109/L) 5.46 2.72
Platelet (109/L) 255 83.4
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summarized in Tables 1 and 2 respectively. Patients had an average of
8.67 ± 7.81 distinct nondiabetic comorbidities, and 0.66 ± 0.90 dia-
betic complications. On average, patients had a median of three (inter-
quartile range = 5) episodes of acute hospital admissions between the
years 2004 and 2008. The three commonest diabetic complications
were retinopathy/maculopathy (16.5%), nephropathy (14.7%), and
hypoglycemia (11.9%), as shown in Table 1. Other pre-existing com-
orbidities were hypertension (36.6%), IHD (16.7%), stroke (12.1%), HF
TABLE 2 (Continued)
Mean SD
Red blood cell (1012/L) 4.25 0.740
White blood cell (109/L) 8.09 2.86
TABLE 3 Multivariable analysis showing predictors of sudden cardiac death (n = 15 316)
Predictor Hazard ratio (HR) 95% confidence interval (CI) p value
Age 1.04 [1.02, 1.05] <.0001
Categorized age 0.977 [0.846, 1.13] 0.747
Male 1.27 [1.15, 1.41] <.0001
Frequency of baseline acute admissions 1.003 [1.003, 1.003] <.0001
Number of concomitant DM complications 1.21 [1.15, 1.27] <.0001
Number of distinct non-DM comorbidities 1.02 [1.01, 1.02] <.0001
Baseline anemia 0.948 [0.861, 1.04] 0.281
Hypoglycemia frequency 1.03 [1.00, 1.07] .032
HbA1c
SD 1.74 [1.45, 2.09] <.0001
Coefficient of variation 0.953 [0.935, 0.972] <.0001
Total cholesterol
SD 0.551 [0.275, 0.951] .034
Coefficient of variation 1.05 [1.02, 1.08] .002
HDL cholesterol
Mean 0.866 [0.609, 1.23] 0.425
SD 0.915 [0.120, 6.99] 0.931
Coefficient of variation 1.00 [0.979, 1.03] 0.769
LDL cholesterol
SD 1.73 [1.10, 2.74] .018
Coefficient of variation 0.978 [0.966, 0.991] .001
Triglyceride
Mean 1.29 [1.17, 1.41] <.0001
SD 0.772 [0.656, 0.909] .002
Coefficient of variation 1.006 [1.00, 1.01] .022
Antidiabetic agent
Sulphonylurea 1.39 [1.25, 1.54] <.0001
Biguanide 0.630 [0.563, 0.704] <.0001
Thiazolidinedione 0.849 [0.652, 1.11] 0.226
Cardiovascular medications
ACEI/ARB 1.02 [0.914, 1.14] 0.724
Beta-blocker 1.24 [1.12, 1.38] <.0001
Calcium channel blocker 1.17 [1.06, 1.30] .002
Diuretic 1.51 [1.35, 1.67] <.0001
Lipid-lowering agents 1.02 [0.915, 1.14] 0.697
Note: Values in bold indicate P < 0.05.
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(10.1%), CKD (9.0%), CLD (5.7%), AMI (5.3%), and COPD (3.4%). The
43.8% patients (n = 10 223, mean daily dose = 95.0 ± 300 mg/day)
were on lipid-lowering agents over the course of follow up.
The baseline biochemical characteristics of the present cohort are
presented in Table 2. The average frequency of baseline hypoglycemic
episodes, between January 1 and December 31 2008, was 0.50 ± 1.31
episodes per year. The baseline hypoglycemia frequency significantly
correlated with all HbA1c and lipid variability indices (p < .0001). Logistic
regression revealed that baseline hypoglycemia frequency was a signifi-
cant predictor of aborted or actual SCD (OR = 1.09, 95% CI = [1.06,
1.12], p < .0001) and incident AF (OR = 1.05, 95% CI = [1.01, 1.08],
p = .007). In total, 2512 and 1846 patients experienced incident SCD
and AF respectively throughout follow-up.
3.1 | Predictors of SCD and AF
In the present cohort, 10.3% of patients suffered from at least one
SCD event, and 7.7% suffered from AF. Amongst these cases, 25 and
10 cases of patients experiencing aborted or actual SCD and AF were
associated with hypoglycemia on admission, respectively. Supplemen-
tary Table 2 and 3 present the univariable Cox regression of
TABLE 4 Multivariable analysis showing predictors of atrial fibrillation (n = 13 267)
Predictor Hazard ratio (HR) 95% confidence interval (CI) p value
Age 1.04 [1.03, 1.06] <.0001
Categorized age 1.09 [0.927, 1.27] 0.307
Male 0.916 [0.816, 1.03] 0.131
Frequency of baseline acute admissions 1.002 [1.002, 1.003] <.0001
Number of concomitant DM complications 1.03 [0.961, 1.09] 0.437
Number of distinct non-DM comorbidities 0.998 [0.991, 1.01] 0.700
Hypoglycemia frequency 1.05 [1.02, 1.09] .005
HbA1c
Mean 1.00 [0.927, 1.08] 0.973
SD 1.31 [0.898, 1.92] 0.161
Coefficient of variation 0.987 [0.954, 1.02] 0.474
Total cholesterol
Mean 1.10 [0.800, 1.50] 0.565
SD 1.05 [0.522, 2.11] 0.893
Coefficient of variation 0.997 [0.961, 1.03] 0.894
HDL cholesterol
Mean 0.907 [0.580, 1.42] 0.668
SD 0.296 [0.030, 2.95] 0.299
Coefficient of variation 1.02 [0.993, 1.05] 0.143
LDL cholesterol
Mean 0.783 [0.566, 1.08] 0.142
SD 1.36 [0.730, 2.55] 0.331
Coefficient of variation 0.992 [0.976, 1.01] 0.340
Triglyceride
Mean 0.968 [0.860, 1.09] 0.589
Antidiabetic agent
Sulphonylurea 1.12 [1.00, 1.26] .043
Biguanide 0.843 [0.746, 0.954] .007
Cardiovascular medications
ACEI/ARB 1.21 [1.06, 1.37] .004
Beta-blocker 1.56 [1.39, 1.75] <.0001
Calcium channel blocker 1.35 [1.20, 1.51] <.0001
Diuretic 1.50 [1.34, 1.69] <.0001
Lipid-lowering agents 1.16 [1.03, 1.32] .018
Note: Values in bold indicate P < 0.05.
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predictors for aborted or actual SCD and AF respectively. Supplemen-
tary Table 4 presents the univariable Cox regression for ventricular
tachycardia alone, with HbA1c and cholesterol variability found to be
predictive (p < .05).
Table 3 summarizes the results of the multivariable analysis for
aborted or actual SCD (n = 15 316), where the following predictors
were independent predictors: (1) Demographics: Age (HR = 1.04, 95%
CI = [1.02, 1.05], p < .0001), male (HR = 1.27, 95% CI = [1.15, 1.41],
p < .0001); (2) Clinical: Frequency of baseline acute admissions
(HR = 1.003, 95% CI = [1.003, 1.003], p < .0001), number of concom-
itant diabetic complications (HR = 1.21, 95% CI = [1.15, 1.27],
p < .0001), number of discrete nondiabetic comorbidities (HR = 1.02,
95% CI = [1.01, 1.02], p < .0001), hypoglycemic frequency
(HR = 1.03, 95% CI = [1.00, 1.07], p = .032); (3) Glycemic and lipid
variability: HbA1c SD (HR = 1.74, 95% CI = [1.45, 2.09], p < .0001)
and CV (HR = 0.953, 95% CI = [0.935, 0.972], p < .0001), total cho-
lesterol CV (HR = 1.05, 95% CI = [1.02, 1.08], p = .002), LDL-C SD
(HR = 1.73, 95% CI = [1.10, 2.74], p = .018), triglyceride mean
(HR = 1.29, 95% CI = [1.17, 1.42], p < .0001) and CV (HR = 1.01,
95% CI = [1.00, 1.01], p = .022); (4) Antidiabetic agent: Sulphonylurea
(HR = 1.39, 95% CI = [1.25, 1.54], p < .0001), biguanide (HR = 0.630,
95% CI = [0.563, 0.704], p < .0001); (5) Cardiovascular medications:
Beta-blocker (HR = 1.24, 95% CI = [1.12, 1.38], p < .0001), diuretic
(HR = 1.51, 95% CI = [1.35, 1.67], p < .0001). CV of HbA1c
(HR = 0.953, 95% CI = [0.935, 0.972], p < .0001) and LDL-C
(HR = 0.978, HR = [0.966, 0.991], p = .001), in addition to SD of total
cholesterol (HR = 0.551, 95% CI = 0.275, 0.951), p = .034) and tri-
glyceride (HR = 0.772, 95% CI = [0.656, 0.909], p = .002) were pre-
dictive of SCD on univariable analysis but became protective after
multivariable analysis.
The findings of multivariable regression analysis for incident AF
(n = 13 267) are presented in Table 4, where several significant pre-
dictors were identified: (1) Demographics: Age (HR = 1.04, 95%
CI = [1.03, 1.06], p < .0001); (2) Clinical: Frequency of baseline acute
admissions (HR = 1.00, 95% CI = [1.00, 1.00], p < .0001), hypoglyce-
mic frequency (HR = 1.05, 95% CI = [1.02, 1.09], p = .005); (3) Anti-
diabetic agent: Sulphonylurea (HR = 1.12, 95% CI = [1.00, 1.26],
p = .043), biguanide (HR = 0.843, 95% CI = [0.746, 0.954], p = .007);
(4) Cardiovascular medication: ACEI/ARB (HR = 1.21, 95% CI = 1.06,
1.37), p = .004), beta-blocker (HR = 1.56, 95% CI = [1.39, 1.75],
p < .0001), CCB (HR = 1.35, 95% CI = [1.20, 1.51], p < .0001),
diuretic (HR = 1.50, 95% CI = [1.34, 1.69], p < .0001), lipid-lowering
agents (HR = 1.16, 95% CI = [1.03, 1.32], p = .018).
4 | DISCUSSION
The present study demonstrated the following major findings: (1) Clini-
cal and biochemical indices are predictive of arrhythmic occurrence
amongst diabetics; (2) Both the mean and variability of HbA1c and
lipid indices can predict VT/VF/SCD in diabetic patients; (3) HbA1c
variability is associated with hypoglycemia frequency. To the best of
our knowledge, the present study is the first to report an association
between increased variability in HbA1c and lipid markers with
increased risk for VT/VF/SCD amongst diabetic patients.
The prognostic values of HbA1c and lipid variability have been
increasingly explored over the past decades. However, prior studies have
mostly focused on the prediction of all-cause mortality or cardiovascular
events12,22 with only a limited number of studies focusing on arrhythmic
or SCD outcomes.23 Although the underlying pathophysiology remains
incompletely elucidated, there are several possible contributing factors
towards the increased arrhythmic risk amongst patients with high glyce-
mic and lipid variability. First, increased glycemic variability is found to be
associated with QTc prolongation and increased QTc dispersion, which
greatly elevates the risk of ventricular tachyarrhythmia.24,25 There is evi-
dence suggesting that QTc prolongation may be triggered by spontane-
ous hypoglycemia due to underlying coronary atherosclerosis or cardiac
autonomic neuropathy.26–29 Antidiabetic agent use may also play a role
in the prognostic value of glycemic variability. Biguanide users are likely
more stable or earlier in the disease course, thus have a lower cardiovas-
cular disease burden. Sulphonylurea use, which was predictive of SCD in
the present study, is known to have an increased risk of hypoglycemia.30
In addition, it has been reported human ether-a-go-go-related gene
(hERG) channel inhibitory effects of some sulphonylurea, which can lead
to QT prolongation.31 Amongst patients on insulin, who have more labile
glucose control, the spontaneous glycemic fluctuations can induce the
occurrence of arrhythmia. Unfortunately, continuous blood glucose mon-
itoring was not available in the present study to demonstrate the associ-
ation between spontaneous glycemic changes and arrhythmic episodes.
Furthermore, structural remodeling as a result of chronic hyper-
glycemia is also involved in the pathogenesis.32–37 HbA1c variability
has been associated with remodeling and fibrosis of the atria and ven-
tricles, which could be arrhythmogenic.38–40 In a recent nationwide
observational study, an association between high lipid variability and
increased risk of new-onset AF was reported, and statins protected
against AF development via the reduction in adverse atrial remo-
deling.41 Moreover, frequent intermittent hypoglycemia can induce
the release of reactive oxygen species,42 thereby leading to increased
oxidative stress, chronic inflammation, and endothelial dysfunction.43
Hypoglycemia itself is arrhythmogenic and can reduce the myocardial
tolerance to ischemia and reperfusion injuries.44,45
Similar to glycemic variability, the increase in oxidative stress with
fluctuations in lipid levels due to atherogenic substance release from
unstable plaque is hypothesized to underlie the increased arrhythmic
risk.12 Indeed, glycemic fluctuations were found to increase the for-
mation of atherosclerotic plaques and thinning the fibrous cap, which
suggests that intermittent hypoglycemia may contribute to lipid vari-
ability as well.46 It should be noted that whilst triglyceride and HDL-C
variability are dependent on glycemic control and other lifestyle fac-
tors, the use of statin plays a significant role in LDL-C variability. The
significant interpersonal variability, as well as the varying effects
between different types of statins on LDL-C variability, reflects the
need for further research on the area.47,48
The change in HbA1c and lipid variability from predictive of SCD,
in univariable analysis, to being protective under multivariable analy-
sis, can be attributed to several causes. The limitation of cohort size
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and multivariate analysis may have selected for patients of more
advanced disease and undergone aggressive control. Given that a J-
shaped association between adverse outcome and both glycemic and
lipid indices have been described, patients with high variability that
returned to the optimal glycemic and lipid range would have had a
better prognosis.16,49,50 Indeed, the duration of exposure to an opti-
mal glycemic range is inversely associated with diabetic retinopathy
progression, even after accounting for the effects of glycemic variabil-
ity.51 Additionally, Ceriello et al. reported that patients with elevations
in both HbA1c and HDL-C variability were at higher risk for diabetic
nephropathy than those with high variability in only one variable,
highlighting the interacting effects between variability markers.52
Therefore, the protective value may be a result of inevitable selection
bias, the protective effects of pharmacotherapy, and the interactions
between different indices.53,54
4.1 | Strengths and limitations
There are four major strengths for the present study: (1) The inde-
pendent, and interdependent predictive effects of clinical and bio-
chemical indices towards SCD and AF were assessed by univariable
and multivariable analysis; (2) The predictive values of both the
value and variability of HbA1c and lipid indices were assessed to
examine the effect of biochemical fluctuations on arrhythmic risk in
diabetics; (3) The inter-relationship between intermittent hypoglyce-
mia, HbA1c and lipid variability and chronic inflammation was exam-
ined to elucidate the underlying pathogenic mechanism; (4) Long
follow-up durations permitted the capture of adverse outcomes over
a long period.
However, several limitations should be recognized. Firstly, the
cohort was limited to type 2 diabetic patients prescribed with insulin,
which can limit the generalizability of the findings. Given that insulin
is only prescribed for diabetic patients in later stages, an advanced dis-
ease state can be inferred for the selected patients. Secondly, the
observational nature of the present study leads to inevitable errors
from missing data, coding errors, and under-coding. A causational rela-
tionship cannot be established from the findings of the observational
study, which can only demonstrate associations. Furthermore, unfor-
tunately, ICD coding does not reflect the frequency of events, thus
the frequency of SCD events was not evaluated. The coding also does
not reflect whether the VT is sustained or associated with hemody-
namic collapse. It is based on the assumption that coded VT is clini-
cally significant as nonsustained VT would be clinically irrelevant thus
not coded into the database. It should be emphasized that a diagnosis
of VT is not the same as SCD, hence the effect of long-term glycemic
variability on the risk of SCD should be interpreted with caution.
Novel therapies, such as GLPA (n = 9) and SGLT-2 transporter inhibi-
tor (n = 0), were not assessed due to the fact that this retrospective
study recruited patients in the year 2009, at which these agents were
not yet developed. Finally, data on blood pressure, body mass index,
echocardiogram, severity of HF and lifestyle were absent, which can
affect the patients' cardiovascular health.
5 | CONCLUSION
Poor glucose control and variability in lipid parameters in diabetic
patients are associated with SCD. These observations suggest
the need to re-evaluate the extent of glycemic control required
for outcome optimization. Further studies on the predictive value
of variability in other glycemic measures, such as fasting and ran-
dom blood glucose, in addition to other methods of measuring
variability, should be performed to further examine the pre-
dictiveness of glycemic variability towards arrhythmias in dia-
betic patients.
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